Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 8 |
| List of Tables | 8 | 1 |
| List of Figures | 9 | 1 |
| Introduction | 10 | 1 |
| Global Markets Direct Report Coverage | 10 | 1 |
| Thrombocytopenia Overview | 11 | 1 |
| Therapeutics Development | 12 | 2 |
| Pipeline Products for Thrombocytopenia Overview | 12 | 1 |
| Pipeline Products for Thrombocytopenia Comparative Analysis | 13 | 1 |
| Thrombocytopenia Therapeutics under Development by Companies | 14 | 2 |
| Thrombocytopenia Therapeutics under Investigation by Universities/Institutes | 16 | 1 |
| Thrombocytopenia Pipeline Products Glance | 17 | 3 |
| Late Stage Products | 17 | 1 |
| Clinical Stage Products | 18 | 1 |
| Early Stage Products | 19 | 1 |
| Thrombocytopenia Products under Development by Companies | 20 | 3 |
| Thrombocytopenia Products under Investigation by Universities/Institutes | 23 | 1 |
| Thrombocytopenia Companies Involved in Therapeutics Development | 24 | 31 |
| 3SBio Inc. | 24 | 1 |
| AkaRx Inc | 25 | 1 |
| Amarillo Biosciences, Inc. | 26 | 1 |
| Amgen Inc. | 27 | 1 |
| arGEN-X BV | 28 | 1 |
| BioLineRx, Ltd. | 29 | 1 |
| Biotest AG | 30 | 1 |
| Boehringer Ingelheim GmbH | 31 | 1 |
| Bolder Biotechnology, Inc. | 32 | 1 |
| Bristol-Myers Squibb Company | 33 | 1 |
| Cellerant Therapeutics, Inc. | 34 | 1 |
| Genosco | 35 | 1 |
| Hansa Medical AB | 36 | 1 |
| Immunomedics, Inc. | 37 | 1 |
| Intas Pharmaceuticals Ltd. | 38 | 1 |
| Jiangsu Hengrui Medicine Co., Ltd. | 39 | 1 |
| Merck &Co., Inc. | 40 | 1 |
| Momenta Pharmaceuticals, Inc. | 41 | 1 |
| Myelo Therapeutics GmbH | 42 | 1 |
| Neumedicines Inc. | 43 | 1 |
| Novartis AG | 44 | 1 |
| Pfizer Inc. | 45 | 1 |
| PhytoHealth Corporation | 46 | 1 |
| Prophylix Pharma AS | 47 | 1 |
| Protalex, Inc. | 48 | 1 |
| Rigel Pharmaceuticals, Inc. | 49 | 1 |
| Shionogi &Co., Ltd. | 50 | 1 |
| Shire Plc | 51 | 1 |
| STATegics, Inc. | 52 | 1 |
| UCB SA | 53 | 1 |
| ViroMed Co Ltd | 54 | 1 |
| Thrombocytopenia Therapeutics Assessment | 55 | 9 |
| Assessment by Monotherapy Products | 55 | 1 |
| Assessment by Target | 56 | 2 |
| Assessment by Mechanism of Action | 58 | 2 |
| Assessment by Route of Administration | 60 | 2 |
| Assessment by Molecule Type | 62 | 2 |
| Drug Profiles | 64 | 81 |
| Antibody for Autoimmune Disorders and Inflammation Drug Profile | 64 | 1 |
| ARGX-113 Drug Profile | 65 | 2 |
| avatrombopag Drug Profile | 67 | 2 |
| BBT-059 Drug Profile | 69 | 1 |
| BI-655064 Drug Profile | 70 | 2 |
| BL-8040 Drug Profile | 72 | 11 |
| BMS-986004 Drug Profile | 83 | 1 |
| BT-595 Drug Profile | 84 | 1 |
| CLT-009 Drug Profile | 85 | 1 |
| eltrombopag olamine Drug Profile | 86 | 6 |
| eltrombopag olamine Drug Profile | 92 | 1 |
| fostamatinib disodium Drug Profile | 93 | 6 |
| GL-2045 Drug Profile | 99 | 1 |
| GSK-2285921 Drug Profile | 100 | 2 |
| Hetrombopag Olamine Drug Profile | 102 | 1 |
| interferon alfa Drug Profile | 103 | 2 |
| lusutrombopag Drug Profile | 105 | 1 |
| M-281 Drug Profile | 106 | 1 |
| MK-8723 Drug Profile | 107 | 1 |
| Monoclonal Antibody to Agonize Thrombopoietin Receptor for Thrombocytopenia Drug Profile | 108 | 1 |
| Monoclonal Antibody to Antagonize FcgR1 for Inflammatory and Autoimmune Disorders Drug Profile | 109 | 1 |
| Monoclonal Antibody to Antagonize FcgRIIa for Inflammatory and Autoimmune Disorders Drug Profile | 110 | 1 |
| Myelo-001 Drug Profile | 111 | 1 |
| NMIL-121 Drug Profile | 112 | 3 |
| Oligonucleotides to Activate miRNA-150 for Thrombocytopenia and Anemia Drug Profile | 115 | 1 |
| PEG-VM501 Drug Profile | 116 | 1 |
| PHN-013 Drug Profile | 117 | 1 |
| PRTX-100 Drug Profile | 118 | 7 |
| Recombinant Enzyme to Inhibit Immunoglobulin G for Autoimmune Diseases Drug Profile | 125 | 1 |
| romiplostim Drug Profile | 126 | 3 |
| romiplostim biosimilar Drug Profile | 129 | 1 |
| SHP-652 Drug Profile | 130 | 3 |
| SKIO-703 Drug Profile | 133 | 1 |
| Small Molecules to Inhibit BLVRB for Thrombocytopenia Drug Profile | 134 | 1 |
| Small Molecules to Inhibit PF4 for Heparin Induced Thrombocytopenia Drug Profile | 135 | 1 |
| STST-4 Drug Profile | 136 | 1 |
| thrombopoietin Drug Profile | 137 | 1 |
| Tromplate Drug Profile | 138 | 1 |
| TXA-302 Drug Profile | 139 | 1 |
| UCB-7665 Drug Profile | 140 | 1 |
| veltuzumab Drug Profile | 141 | 4 |
| Thrombocytopenia Dormant Projects | 145 | 3 |
| Thrombocytopenia Discontinued Products | 148 | 1 |
| Thrombocytopenia Product Development Milestones | 149 | 13 |
| Featured News &Press Releases | 149 | 1 |
| Oct 20, 2016: Rigel Announces Results from the Second FIT Phase 3 Study and the Long-Term Open-Label Extension Study for Fostamatinib in ITP | 149 | 1 |
| Oct 06, 2016: Amarillo Biosciences Receives Approval of Patent Claims - Treatment of Thrombocytopenia Using Orally Administered Interferon | 150 | 1 |
| Sep 22, 2016: argenx provides update on lead program ARGX-113 at R&D day in New York | 151 | 1 |
| Sep 15, 2016: Rigel Restructures to Focus on Fostamatinib Commercialization | 151 | 1 |
| Aug 30, 2016: Rigel Fostamatinib Meets Primary Endpoint in Phase 3 Study in Chronic ITP | 152 | 1 |
| Aug 25, 2016: Health Canada issues advisory on REVOLADE citing risk of severe hepatotoxicity | 153 | 1 |
| Jun 10, 2016: Novartis highlights long-term safety data of Revolade in adults with chronic immune thrombocytopenia, a rare blood disorder | 154 | 1 |
| May 19, 2016: Amgen Highlights Data on Nplate (romiplostim) at 21st Congress Of The European Hematology Association | 155 | 1 |
| Apr 19, 2016: Nplate (Romiplostim) Study In The Lancet Shows Significant Increase In Durable Platelet Response Among Children With Immune Thrombocytopenia | 156 | 1 |
| Apr 07, 2016: Novartis receives EU approval for Revolade as first-in-class therapy for children aged 1 year and above with chronic ITP | 157 | 1 |
| Apr 01, 2016: Rigel Completes Enrollment of FIT Phase 3 Program for Fostamatinib in ITP | 158 | 1 |
| Jan 29, 2016: CHMP adopts extension to existing therapeutic indication for eltrombopag | 159 | 1 |
| Jan 28, 2016: Rigel Completes Enrollment of First Phase 3 Study of Fostamatinib in ITP | 159 | 1 |
| Jan 07, 2016: Rigel Reviews Recent Progress and Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco | 160 | 1 |
| Dec 01, 2015: Shionogi Launches MULPLETA Tablets 3mg In Japan for Improvement of Thrombocytopenia | 161 | 1 |
| Appendix | 162 | 2 |
| Methodology | 162 | 1 |
| Coverage | 162 | 1 |
| Secondary Research | 162 | 1 |
| Primary Research | 162 | 1 |
| Expert Panel Validation | 162 | 1 |
| Contact Us | 162 | 1 |
| Disclaimer | 163 | 1 |